



SURVEILLANCE- MORE THAN A 
RESEARCH TOOL 
The monotonic increase in South African malaria cases, with an 
over 100-fold increase in notifications during the past three 
decades, from 364 notified cases in 1971 to 51 433 cases in 1999, 
has elicited consternation throughout the public health sector. ' 
Although this dramatic increase is clearly multifactorial, 
resulting from the effects of meteorological changes, human 
parasite-carrier migratory patterns, resistance of a mosquito 
vector (Anopheles arabiensis) to synthetic pyrethroid insecticides 
and an inconsistent notification system, the contribution of 
ineffective first-line malaria therapy should not be 
underestimated. The situation in KwaZulu-Natal (KZN) 
deserves particular mention, given this province's increasing 
proportional contribution to the national malaria burden. A 
recent dramatic increase in case numbers in KZN and 
anecdotal reports from clinic staff of patients returning with 
recurrence of symptoms within 2 weeks of treatment with 
sulfadoxine-pyrimethamine (SP) raised the alarm that the 
province might be in the grip of high-grade malaria parasite 
(Plasmodium falciparum) resistance to SP. Earlier results of a 
small1996 hospital-based study found a 23.5% RI / Rll/RIII 
parasitological failure rate on SP therapy (Medical Research 
Council - unpublished data). Although this finding was 
inconclusive because of the possibility of referral selection bias, 
it should have prompted an urgent, through evaluation of the 
effectiveness of SP therapy. The establishment of a sentinel 
surveillance site in KZN could have addressed this need. 
Resistance of P. falciparum to antimalarial drugs is a serious 
impediment to controlling malaria.2"' P. falciparum resistance to 
chloroquine was first reported in Africa in 1979, while clinical 
evidence of P. Jalcipantm resistance to chloroquine emerged in 
South Africa during the mid-1980s."" Despite resistance, 
chloroquine is often still used in areas of stable malaria because 
of the additive effect of host immune factors resulting in 
clinical but not parasitological cure. In South Africa, however, 
where the majority of the population resident in malaria areas 
are unlikely to enjoy any immunity, the risk of rapid 
progression to severe disease and even death necessitates 
1rmr;. effective first-line therapy that will rapidly eliminate P. 
• ~ Jalciparum and effect a parasitological cure. Thus the findings of 
in vitro tests demonstrating high levels of chloroquine 
resistance in KZN and Mpumalanga, and a striking increase in 
positive follow-up smears after chloroquine therapy in 
Mpumalanga, from 1.7% in 1990 to 16.7% in 1995, demanded 
confirmation by a carefully conducted in vivo evaluation .... 0 
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Following examples in other countries, Mpumalanga 
established sentinel site at Naas and Mangweni health centre. 
in their most affected malaria districts for collecting in vivo 
resistance data. A standardised chloroquine in vivo study, baSE j 
on the World Health Organisation (WHO) protocol, with 28-
day follow-up, was conducted at these health centres during 
1997." Unacceptable levels of Rll/ RIII (moderate to high lev 
parasitological failure (17.9%) and clinical failure (24%) were 
documented in Mpumalanga, with the total RI/Rll/RIII 
parasitological failure rate being 48.4% (Freese J A, Report to 
the Department of Health). Similar patterns were found in 
Northern Province (RI/Rll/RIII of 40%) and KZN (RI/Rll /RI ! 
of 62.5%) during surveys of smaller numbers of patients. This 
catalysed a national policy change from chloroquine to SP for 
first-line malaria treatment, although KZN had already made 
this change a decade earlier in 1988. 
The same sentinel sites in Mpumalanga were used to 
conduct an informative baseline in vivo SP resistance survey c 1 
introduction of the change in first-line treatment.15 This 
evaluation, with 42-day follow-up, confirmed the efficacy of ~ ? 
firs t-line therapy and demonstrated slower resolution of 
clinical symptoms than parasite clearance. In addition, it raisl i 
important questions about the adequacy of the recommendec 
SP dosage for adults exceeding 60 kg, and the viability of 
gametocytes found to peak 7 - 14 days after therapy. The 
results of the most recent evaluation conducted 2 years after ~ ? 
introduction at the same site in Mpumalanga (in this issue of 
the journal) confirm the continued efficacy of SP.'6 This findin , 
raises the possibility that SP usefulness may be extended 
through combination with artesunate, thus sustaining 
affordable therapy in Mpumalanga. 17 This is necessary, since 
when used as monotherapy, resistance to SP has been shown o 
emerge more rapidly than resistance to chloroquine. Once hi£'1 
levels of SP resistance exist, few affordable treatment opti_ons 
remain. 
The discovery of high-level failure of SPin the treatment of 
uncomplicated malaria in KZN, found in the standardised in 
vivo study conducted at clinic level in KZN in this issue of thl 
journal), confirms concerns regarding the effectiveness of SP in 
this province. '" More alarmingly, this has precluded the use of 
the SP-artesunate combination in KZN. Although the true 
impact of persistent use of failed SP first-line therapy during 
the recent past in KZN on morbidity, mortality, economic 
losses, malaria transmission and resultant public health 
expenditure cannot be accurately determined, the resulting 
crisis could have been circumvented had regular clinic-level 
sentinel surveillance been conducted . 
Public health surveillance has many uses, the most well 
known being detection of epidemics, evaluation of control and 
prevention activities, detection of changes in health practice, 
quantitative estimates of the magnitude of health problems, 
and monitoring of changes in infectious agents, particularly the 
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' ,•olution of drug resistance.'• Although the term 'surveillance' 
' ·as initially restricted to the collection, analysis and 
, issemination of data and did not encompass direct 
: •sponsibility for responding to findings, more recently the 
, . .1ality of surveillance has been judged by its capacity to 
; rovide 'data for action'.20-22 
Sentinel surveillance encompasses those activities focused 
• :1 monitoring key health indicators in the general population 
1bgroups. The term sentinel is applied to health events, 
1 eluding cholera, malaria or maternal deaths, which provide a 
arning signal that the quality of preventive or therapeutic 
•alth services merits investigation.n.1• Sentinel surveiUance 
so refers to specifically chosen sites, whether health facilities 
• · health providers, where data that are not routinely available 
e collected.25 Careful selection of sites allows for adequate 
sources, including experienced and dedicated personnel, for 
• •llecting detailed information on each case and providing 
reful follow-up. As the collection of data is the most costly 
.d difficult component of any surveillance system, it is 
t sential that all elements to assure quality, reliability and 
t liformity of data are in place.26 These include the ease of data 
c llection facilitated by clarity, simplicity and lack of 
• 1biguity of standardised forms and flow charts; well-defined 
c se definitions; timeliness; mechartisrns for preven ting loss to 
l ow-up; and measures to motivate data collectors, including 
1 'dback, participation in planning and review, recognition and 
• 'ler incentives. 
ln selecting a sentinel surveillance site, consideration must be 
<en to a number of issues. These include the particular 
F 1rpose of surveillance, frequency of the health event 
( :curacy of sample estimate), available resources, feasibility, 
t ~ need to generalise findings (external validi ty), duration 
(. ends) and likely quality of data (internal validity). Use of 
h ·spitals or other sophisticated facilities may pose problems 
b. cause of the selection bias that usually operates.27 However, 
h 'spitals are particularly valuable sites for tracking mortality 
hends or for detecting severe diseases that are almost 
iDevitably admitted.".l9 
South Africa has been tardy in recogrtising the potential 
value of sentinel sites. A number of malaria control 
programmes in other African and South-East Asian countries 
have an established tradition of assessing the efficacy of their 
first-line malaria therapeutic regimens a t sentinel surveiUance 
ites to guide public health policy. In recent years both Zambia 
and Malawi have altered their national malaria treatment 
policies on the basis of results from standardised in vivo studies 
conducted at sentinel clinics.303' 
Malaria sentinel sites may serve additional valuable 
functions. In particular, their usefulness as an epidemiological 
early warnmg system for malaria epidemics is being 
increasingly realised . The alarm is triggered when monthly 
rnorbidity thresholds set for particular clinics are exceeded.l2·" 
Mpumalanga has also harnessed the capacity developed at its 
sentinel sites to field test the accuracy and utility of rapid 
malaria d iagnostic tests.».36 The seasonal nature of malaria 
transmission in South African creates the opporturlity for using 
the capacity developed at these sites to the benefit of other 
public health programmes. 
The need for a sentinel surveillance network as a prerequisite 
fo r epidemiological research and health planning in South 
Africa was mooted more than 60 years ago.37 This plea appears 
to have been vindicated by the high-quality drug efficacy 
information and da ta on the accuracy of diagnostic tests 
already collected at the malaria sentinel sites in South Africa 
that have facilita ted major policy changes. The proposed plan 
to establish similar sites in KZN, Northern Province, Swaziland 
and Mozambique should therefore be vigorously pursued. 
However, the true value of these si tes will not be measured by 
the volume of information they generate, but by the public 
health actions triggered . 
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F AlLURE O F SULPHADO XINE-PYRIMETHAMINl 
IN TREATING PLASMODIUM FALCIPARUM 
MALARIA IN K wAZ ULU-NATAL 
To the Editor: Sulphadoxine-pyrimethamine (SP) has been in 
use as the first-line curative drug for Plasmodium Jalciparum 
malaria in KwaZulu-Natal, South Africa since January 1988. l. 
replaced chloroquine, to which resistance had been 
demonstrated. 
There is widespread concern about the rate at which 
resistance has developed to SP elsewhere in the world, with 
anecdotal evidence suggesting that substantial resistance to it 
had developed in the malarious areas of KwaZulu-Natal. ' 
Evolution of resistance may be exacerbated by SP's long half-
life, with parasites therefore exposed to subtherapeutic drug 
concentrations for relatively long periods of time. 
An in v ivo study was conducted on patients attending the 
malaria clinic at Ndumo, KwaZulu-Natal. Patients were treat ·d 
with SP and followed up daily for 3 days and thereafter at 7, 
14, 21, 28 and 42 days post-treatment. 
Ndumo clinic, in the Ingwavuma district of KwaZulu-Nat, l, 
is a satellite clinic of the Mosvold Hospital, and serves a rura 
population of approximately 15 000 people. Malaria 
transmission in this district is predominantly seasonal and ti- ~ 
population is not thot...ght to have acquired significant levels ,f 
immunity_ 
Patients diagnosed positive with malaria by the clinic staff 
were referred to the study team. They were retested with a 
rapid immunochromatographic diagnostic system (ICT MLC , 
AMRAD Operations, Pty Ltd, Australia), and informed consr nt 
was obtained from patients before proceeding with enrolmer :. 
Thick and thin blood smears were prepared from finger-pric' 
blood and stained with Giemsa's stain. The standard in vivo 
inclusion criteria and detailed methodology used have been 
described elsewhere.' 
SP tablets were administered as a single oral dose (25 mg 
sulphadoxine plus 1.25 mg pyrimethamine per kilogram bo V 
weight) and patients were asked to return on each of days 1, 2, 
3, 7, 14, 21, 28 and 42. Parasitological evaluation using 
quantitative microscopy of Giemsa-stained blood smears was 
undertaken by the clinic microscopist, and clinical evaluation, 
including measurement of oral temperature and assessment of 
symptoms, was done by the research team at each visit. 
Parasitaemia occurring in patients after day 21 was 
investigated with polymerase chain reaction amplifications of 
the genetic markers MSP1, MSP2 and GLURP1 and 2 in order 
to differentiate between true recrudescence of the original 
infection and possible new infections.' 
At least 79 of the 129 enrolled patients failed (61.2%), but this 
may have been as high as 79/90 (87.8%) if those patients lost to 
follow-up are excluded from the analysis. The results of the 90 
patients followed up to day 42 or failure are reflected in Table J. 
